FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045793565> ?p ?o ?g. }

• W2045793565 endingPage "1203" @default.
• W2045793565 startingPage "1191" @default.
• W2045793565 abstract "The stimulant prodrug lisdexamfetamine dimesylate (LDX) is an effective and generally well tolerated treatment for the symptoms of attention-deficit/hyperactivity disorder (ADHD). Positive impacts of LDX on health-related quality of life and functional impairment have previously been demonstrated in a 7-week, randomized, double-blind, placebo-controlled, phase III study in children and adolescents in Europe. Maintenance of these broad benefits, as well as symptomatic control, is a key goal of long-term management of ADHD. Secondary objectives of this multinational study in children and adolescents with ADHD were to assess the long-term maintenance of effectiveness of LDX in improving health-related quality of life and reducing functional impairment, as gauged using the Child Health and Illness Profile-Child Edition: Parent Report Form (CHIP-CE: PRF) and the Weiss Functional Impairment Rating Scale-Parent Report (WFIRS-P), respectively. Patients aged 6–17 years with diagnosed ADHD and a baseline ADHD Rating Scale IV total score of at least 28 were enrolled from the previous European study and from US sites. Patients who completed an open-label LDX treatment period of at least 26 weeks were randomized (1:1) to continue on their optimized dose of LDX or to switch to placebo for a 6-week, double-blind, withdrawal period. Parents completed CHIP-CE: PRF and WFIRS-P questionnaires at weeks 0, 8 and 26 of the open-label period and at weeks 0 and 6 of the randomized-withdrawal period, or at early termination. The endpoint of each period was defined as the last visit with valid data. Effect sizes were the difference (LDX minus placebo) in least-squares (LS)-mean change from baseline to endpoint divided by root-mean-square error. P values were nominal and not adjusted for multiple comparisons. The open-label and randomized full analysis sets comprised 262 and 153 (LDX n = 76; placebo n = 77) patients, respectively. Mean pretreatment CHIP-CE: PRF T-scores were more than one standard deviation below the normative mean in four of the five domains, and there was significant improvement across all domains from baseline to endpoint of the open-label period. In the randomized-withdrawal period, LS-mean CHIP-CE: PRF T-scores deteriorated in all domains in the placebo group, but not in the LDX group. Compared with placebo, the effect of LDX was significant in the Risk Avoidance (effect size 0.829; p < 0.001), Achievement (0.696; p < 0.001) and Satisfaction (0.636; p < 0.001) domains. Mean pretreatment WFIRS-P scores were lowest in the Family domain and the Learning and School domain. WFIRS-P total score and scores in all domains improved significantly from baseline to endpoint of the open-label period. In the randomized-withdrawal period, LS-mean scores deteriorated in the placebo group but not in the LDX group. Compared with placebo, the effect of LDX was significant in the Family, Learning and School, and Risky Activities domains and in total (effect size 0.908; p < 0.001). Using parent-rated instruments, long-term maintenance of the beneficial effect of LDX in multiple domains of health-related quality of life and functional impairment was demonstrated by comparison of treatment continuation and withdrawal under randomized, double-blind, placebo-controlled conditions." @default.
• W2045793565 created "2016-06-24" @default.
• W2045793565 creator A5000058346 @default.
• W2045793565 creator A5015721926 @default.
• W2045793565 creator A5016008616 @default.
• W2045793565 creator A5039645834 @default.
• W2045793565 creator A5052484169 @default.
• W2045793565 creator A5052792299 @default.
• W2045793565 creator A5064064053 @default.
• W2045793565 creator A5070385935 @default.
• W2045793565 date "2014-08-20" @default.
• W2045793565 modified "2023-10-01" @default.
• W2045793565 title "Health-Related Quality of Life and Functional Outcomes from a Randomized-Withdrawal Study of Long-Term Lisdexamfetamine Dimesylate Treatment in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder" @default.
• W2045793565 cites W1971838314 @default.
• W2045793565 cites W1973439065 @default.
• W2045793565 cites W1974896478 @default.
• W2045793565 cites W1979206088 @default.
• W2045793565 cites W1989444430 @default.
• W2045793565 cites W1993327116 @default.
• W2045793565 cites W1999725272 @default.
• W2045793565 cites W2023262882 @default.
• W2045793565 cites W2028637191 @default.
• W2045793565 cites W2037557484 @default.
• W2045793565 cites W2041139943 @default.
• W2045793565 cites W2042644970 @default.
• W2045793565 cites W2066865689 @default.
• W2045793565 cites W2083388738 @default.
• W2045793565 cites W2085942575 @default.
• W2045793565 cites W2086997214 @default.
• W2045793565 cites W2090672792 @default.
• W2045793565 cites W2117267641 @default.
• W2045793565 cites W2127512142 @default.
• W2045793565 cites W2129620184 @default.
• W2045793565 cites W2131679908 @default.
• W2045793565 cites W2150988818 @default.
• W2045793565 cites W2163817145 @default.
• W2045793565 cites W2168895300 @default.
• W2045793565 cites W25938887 @default.
• W2045793565 cites W3177640887 @default.
• W2045793565 cites W4247665917 @default.
• W2045793565 doi "https://doi.org/10.1007/s40263-014-0193-z" @default.
• W2045793565 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4246127" @default.
• W2045793565 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25139785" @default.
• W2045793565 hasPublicationYear "2014" @default.
• W2045793565 type Work @default.
• W2045793565 sameAs 2045793565 @default.
• W2045793565 citedByCount "34" @default.
• W2045793565 countsByYear W20457935652015 @default.
• W2045793565 countsByYear W20457935652016 @default.
• W2045793565 countsByYear W20457935652017 @default.
• W2045793565 countsByYear W20457935652018 @default.
• W2045793565 countsByYear W20457935652019 @default.
• W2045793565 countsByYear W20457935652020 @default.
• W2045793565 countsByYear W20457935652021 @default.
• W2045793565 countsByYear W20457935652022 @default.
• W2045793565 countsByYear W20457935652023 @default.
• W2045793565 crossrefType "journal-article" @default.
• W2045793565 hasAuthorship W2045793565A5000058346 @default.
• W2045793565 hasAuthorship W2045793565A5015721926 @default.
• W2045793565 hasAuthorship W2045793565A5016008616 @default.
• W2045793565 hasAuthorship W2045793565A5039645834 @default.
• W2045793565 hasAuthorship W2045793565A5052484169 @default.
• W2045793565 hasAuthorship W2045793565A5052792299 @default.
• W2045793565 hasAuthorship W2045793565A5064064053 @default.
• W2045793565 hasAuthorship W2045793565A5070385935 @default.
• W2045793565 hasBestOaLocation W20457935651 @default.
• W2045793565 hasConcept C118552586 @default.
• W2045793565 hasConcept C126322002 @default.
• W2045793565 hasConcept C138496976 @default.
• W2045793565 hasConcept C142724271 @default.
• W2045793565 hasConcept C15744967 @default.
• W2045793565 hasConcept C168563851 @default.
• W2045793565 hasConcept C187212893 @default.
• W2045793565 hasConcept C204787440 @default.
• W2045793565 hasConcept C27081682 @default.
• W2045793565 hasConcept C2779951463 @default.
• W2045793565 hasConcept C2780557958 @default.
• W2045793565 hasConcept C2780783007 @default.
• W2045793565 hasConcept C542102704 @default.
• W2045793565 hasConcept C71924100 @default.
• W2045793565 hasConcept C83849319 @default.
• W2045793565 hasConceptScore W2045793565C118552586 @default.
• W2045793565 hasConceptScore W2045793565C126322002 @default.
• W2045793565 hasConceptScore W2045793565C138496976 @default.
• W2045793565 hasConceptScore W2045793565C142724271 @default.
• W2045793565 hasConceptScore W2045793565C15744967 @default.
• W2045793565 hasConceptScore W2045793565C168563851 @default.
• W2045793565 hasConceptScore W2045793565C187212893 @default.
• W2045793565 hasConceptScore W2045793565C204787440 @default.
• W2045793565 hasConceptScore W2045793565C27081682 @default.
• W2045793565 hasConceptScore W2045793565C2779951463 @default.
• W2045793565 hasConceptScore W2045793565C2780557958 @default.
• W2045793565 hasConceptScore W2045793565C2780783007 @default.
• W2045793565 hasConceptScore W2045793565C542102704 @default.
• W2045793565 hasConceptScore W2045793565C71924100 @default.
• W2045793565 hasConceptScore W2045793565C83849319 @default.
• W2045793565 hasIssue "12" @default.
• W2045793565 hasLocation W20457935651 @default.

• next